



Our STN: BL 125562/0

PROPRIETARY NAME ACCEPTANCE

Cangene Corporation
Attention: Ms. Allison Kennedy
155 Innovation Drive
Winnipeg, Manitoba
Canada R3T 5Y3

Dear Ms. Kennedy:

We have reviewed your submission dated July 25, 2014, to your biologics license application (BLA) for Anthrax Immune Globulin Intravenous (Human) requesting a proprietary name review.

In consultation with CBER's Advertising and Promotional Labeling Branch (APLB) we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, Anthrasil, is acceptable at this time.

If you have any questions, please contact Iliana Valencia at (240) 402 – 8444.

Sincerely yours,

Basil Golding MD
Director
Division of Hematology Research and Review
Office of Blood Research and Review
Center for Biologics
Evaluation and Research